261 related articles for article (PubMed ID: 32877695)
1. Vesicular Stomatitis Virus Encoding a Destabilized Tumor Antigen Improves Activation of Anti-tumor T Cell Responses.
Huff AL; Evgin L; Thompson J; Kottke T; Driscoll CB; Tonne J; Wongthida P; Schuelke M; Shim KG; Mer G; Ramirez-Alvarado M; Vile R
Mol Ther; 2020 Dec; 28(12):2540-2552. PubMed ID: 32877695
[TBL] [Abstract][Full Text] [Related]
2. Measles Vaccines Designed for Enhanced CD8
Busch E; Kubon KD; Mayer JKM; Pidelaserra-Martí G; Albert J; Hoyler B; Heidbuechel JPW; Stephenson KB; Lichty BD; Osen W; Eichmüller SB; Jäger D; Ungerechts G; Engeland CE
Viruses; 2020 Feb; 12(2):. PubMed ID: 32098134
[TBL] [Abstract][Full Text] [Related]
3. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
[TBL] [Abstract][Full Text] [Related]
4. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
[TBL] [Abstract][Full Text] [Related]
5. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
Herrera OB; Brett S; Lechler RI
Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
[TBL] [Abstract][Full Text] [Related]
8. Antigen encoded by vaccine vectors derived from human adenovirus serotype 5 is preferentially presented to CD8+ T lymphocytes by the CD8α+ dendritic cell subset.
Suleman M; Galea S; Gavard F; Merillon N; Klonjkowski B; Tartour E; Richardson J
Vaccine; 2011 Aug; 29(35):5892-903. PubMed ID: 21723900
[TBL] [Abstract][Full Text] [Related]
9. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
10. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
Leveille S; Goulet ML; Lichty BD; Hiscott J
J Virol; 2011 Dec; 85(23):12160-9. PubMed ID: 21917977
[TBL] [Abstract][Full Text] [Related]
11. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
12. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
[TBL] [Abstract][Full Text] [Related]
13. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
14. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
16. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens.
Schirmbeck R; Reimann J; Kochanek S; Kreppel F
Mol Ther; 2008 Sep; 16(9):1609-16. PubMed ID: 18612271
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a recombinant influenza virus bearing both the CD4+ and CD8+ T cell epitopes of ovalbumin.
Garulli B; Di Mario G; Sciaraffia E; Kawaoka Y; Castrucci MR
J Biomed Biotechnol; 2011; 2011():497364. PubMed ID: 22007143
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
19. Probiotic lactic acid bacteria promote anti-tumor immunity through enhanced major histocompatibility complex class I-restricted antigen presentation machinery in dendritic cells.
Saito S; Okuno A; Peng Z; Cao DY; Tsuji NM
Front Immunol; 2024; 15():1335975. PubMed ID: 38605963
[TBL] [Abstract][Full Text] [Related]
20. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.
Bridle BW; Boudreau JE; Lichty BD; Brunellière J; Stephenson K; Koshy S; Bramson JL; Wan Y
Mol Ther; 2009 Oct; 17(10):1814-21. PubMed ID: 19603003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
